Drug Profile
NEO PV 01
Alternative Names: Neo Vax; NEO-PV-01; Neoantigen vaccine; Neoantigen-based vaccine - BioNTech; NeoAntigen-peptides; Personalized-neoantigen-cancer-vaccine-BioNTech; Personalized-neoantigen-vaccine-BioNTechLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Broad Institute; Dana-Farber Cancer Institute
- Developer BioNTech; Bristol-Myers Squibb; Celldex Therapeutics Inc; Dana-Farber Cancer Institute; Merck Sharp & Dohme; National Institutes of Health (USA); Neon Therapeutics; Oncovir; Washington University School of Medicine
- Class Cancer vaccines; Peptide vaccines
- Mechanism of Action Immunoglobulin stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Chronic lymphocytic leukaemia; Malignant melanoma
- No development reported Bladder cancer; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Renal-cell-carcinoma(Late-stage disease, Metastatic disease) in USA (Parenteral, Injection)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, First-line therapy) in USA (Parenteral)
- 08 Nov 2021 Washington University School of Medicine and National Cancer Institute plans a phase I trial for Adenocarcinoma (Newly-diagnosed, Combination therapy) in USA (IM) (NCT05111353)